Your Payer's QPA May Not Reflect Market Reality

The new IDR final rule cuts dispute fees by 87%. Here's what that means for community hospitals and ASCs that have been leaving money on the table.

On May 28, HHS finalized a rule that fundamentally changes the economics of out-of-network payment disputes under the No Surprises Act. If you run a community hospital or ambulatory surgery center and you've been ignoring the Independent Dispute Resolution process because the math didn't work, it's time to take another look.

What changed

The headline number: the administrative fee for filing an IDR dispute dropped from $115 to $15 per party per dispute. That's an 87% reduction.

But the batching change may matter more. The new rule allows up to 50 items and services to be resolved in a single dispute batch. Previously, the batching rules were more restrictive, which meant providers had to file — and pay for — separate disputes for related claims that could have been handled together.

For a community hospital with 30 out-of-network claims against a single payer, the old math was roughly $3,450 in administrative fees alone before you even started assembling your case. The new math conservatively is $450. If the claims qualify as a batch, that $3,450 could become just $15 — for thirty total claims. That changes the calculus for smaller organizations that couldn't justify the overhead.

The QPA transparency problem

The Qualifying Payment Amount is supposed to represent the payer's median in-network rate for a given service in the same geographic region, based on 2019 contracted rates indexed for inflation. The payer calculates it. The payer reports it. And the provider is expected to evaluate whether it's reasonable — without seeing the underlying rate data that went into the calculation.

This has been a persistent frustration for providers. The QPA is a black box. You're told "our median rate for this service is $X" and you either accept it or challenge it, but you've historically had limited independent evidence to evaluate whether that number is accurate.

Here's what's changed in the past few years that most community hospital finance teams haven't fully absorbed: the same federal transparency mandates that created the No Surprises Act also created the Transparency in Coverage rule, which requires payers to publish their negotiated in-network rates in machine-readable files. Those files contain the actual rates the payer has negotiated with every in-network provider, for every covered service, in every geography.

That data exists. It's public. And it gives providers, for the first time, an independent way to evaluate whether a payer's QPA is in the right ballpark.

Why this matters beyond the fee reduction

The real story isn't the fee. It's the volume problem the fee was masking.

Since the IDR portal launched in April 2022, more than 5 million disputes have been filed. The system was designed with the expectation that most disagreements would be resolved during the 30-day open negotiation window before IDR. That hasn't happened. Disputes are flooding into arbitration because the initial payment offers from payers — anchored to their Qualifying Payment Amount calculations — are often dramatically below what IDR entities ultimately determine is fair.

How dramatically? Public data from IDR outcomes shows that the typical arbitration award is nearly 9 times the QPA benchmark set by insurers. Providers are winning roughly 85% of decided cases.

For medium-intensity emergency department visits alone, the median IDR award was $795 when the median in-network payment for the same service in the same markets was $140.

(While this claim is supported by the linked Health Affairs article, past performance does not dictate future results.)

Those numbers tell you something important: in many cases, the QPA alone may not fully reflect the payment amounts ultimately determined by IDR entities.

Why this matters beyond out-of-network issues

One of the less discussed aspects of the IDR is that it creates an external reference point for a payer/provider negotiation environment that has historically lacked one. Payers and providers routinely disagree about what constitutes a reasonable payment amount. The IDR process introduces an independent assessment into that discussion. A consistent pattern of outcomes can provide valuable intelligence about how market evidence, provider characteristics, and reimbursement levels are viewed by neutral, third-party decision makers. This becomes a source of information that will influence many future contracting discussions.

What this looks like in practice

Say your ASC receives an initial payment on an out-of-network claim for a knee arthroscopy at $1,200, with the payer citing a QPA of $1,350. You think the payment should be significantly higher, but you have no way to know what the payer is actually paying other facilities for the same procedure in your market.

With Transparency in Coverage data, you can answer that question directly. You can see the negotiated rates for every in-network ASC and hospital outpatient department within your service area for that exact CPT code. If the median current in-network rate across comparable facilities is materially higher than the QPA, you now have independent, publicly sourced evidence that the QPA-based payment dramatically understates the market.

That evidence goes into your IDR submission alongside your payment offer. The IDR entity is required to consider multiple factors beyond just the QPA, including the provider's level of training and experience, the market share of the parties, and — critically — any information the parties submit about the appropriate payment amount. Systematic market rate evidence from the payer's own published data is exactly the kind of information that supports a provider's case.

What community hospitals and ASCs should be doing right now

First, take stock of your out-of-network claims. How many out-of-network claims have you written off or accepted substandard payment on in the past 12 months because the IDR process seemed too expensive or too cumbersome? With fees at $15 per dispute and batching up to 50 items, revisit that calculation.

Second, look at the QPAs you've been receiving. When a payer sends an initial payment or denial with a QPA disclosure, are you evaluating whether that QPA is reasonable? Or are you filing it and moving on? The public rate data to challenge unreasonable QPAs exists — the question is whether you have the capacity to use it.

Third, think about your negotiation leverage. IDR outcomes feed back into the broader payer relationship. A payer that knows you're willing and able to pursue IDR disputes with strong market evidence is a payer that's more likely to offer reasonable rates during in-network contract negotiations. The IDR process and in-network contracting aren't separate activities — they're two levers on the same relationship.

Fourth, build the analytical foundation now. The providers who will benefit most from the lower IDR fees are those who can efficiently produce rate evidence packages — not just for one dispute, but systematically across their out-of-network volume. If you don't have access to Transparency in Coverage rate data for your market and your payers, start exploring how to get it. The data is public, but the files are massive and require significant processing to turn into usable intelligence.

The bigger picture

The combination of price transparency mandates and the No Surprises Act was always supposed to create a more level playing field between payers and providers. For large health systems with dedicated analytics teams, that's already happening. For community hospitals, ASCs, and independent practices, the playing field has been level in theory but not in practice — because these organizations haven't had the resources to process transparency data or the budget to pursue IDR disputes.

The final rule addresses the budget constraint. The data constraint is the remaining barrier. The organizations that solve it will find themselves in a fundamentally stronger position — both in dispute resolution and in every payer negotiation that follows.

A word of caution

While metrics mentioned in this post are currently supported by publicly available data, past performance may not be indicative of future results. Transparency data is not a substitute for a comprehensive IDR strategy. Rate comparisons must be normalized for geography, provider type, service setting, and contract structure. However, independent market evidence can provide an important reference point when evaluating whether a QPA appears reasonable.